US FDA grants priority review status for Novartis' Glivec for GIST
Thursday, August 28, 2008 09:00 IST Basel
Novartis announced that Glivec (imatinib) has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumours
